Gulam Manji
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gulam Manji sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Gulam Manji: 5 sponsored US clinical trials, 2 recruiting.
Gulam Manji sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adenocarcinoma of the Pancreas, with 1 trials.
Upper-quartile sponsor footprint
Gulam Manji sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
NCT06048484
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
NCT04543071
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
NCT03979066
Perioperative Chemo and Pembrolizumab in Gastric Cancer
NCT02918162
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
NCT02584647
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Therapeutic Areas
What is open in the Gulam Manji pipeline
2 recruiting of 5 indexed (40% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Adenocarcinoma of the Pancreas (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gulam Manji: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Gulam Manji sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Gulam Manji page
5 registered trials is a research-attention snapshot, not an endorsement of Gulam Manji or any single study.
- 2 of Gulam Manji's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adenocarcinoma of the Pancreas is the condition Gulam Manji studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adenocarcinoma of the Pancreas trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gulam Manji pipeline card: 5 registered trials from official public datasets.Report a data error.